Intercure Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Intercure Ltd (INCR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Intercure Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 270M vs 1,720M combined for its competitors (13.6% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs decelerating (-17.6%) for its tracked peer group.
- Growth: Intercure Ltd generated 318.4% revenue growth year over year in Q4 2025, vs -11.7% for its competitors combined.
- Profitability: Its -13.6% net margin compares with -40.1% for the peer group.
- Scale: Intercure Ltd ranks #339 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Intercure Ltd accounted for 43.3% of combined revenue among its tracked peer group, up from 13.9% a year earlier.
- Peer differentiation: Revenue per employee of $0.60M compares with $0.31M for the peer group (1.9x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
INCR Sales vs. its Competitors, Q4 2025
Intercure Ltd reported revenue growth of 318.38 % year on year in Q4 2025, above its competitors' combined revenue change of -11.68 %.
With a net margin of -13.61 %, Intercure Ltd achieved higher profitability than its competitors (-40.06 %).
Intercure Ltd generated 43.26 % of the combined sales of its peer group, up from 13.86 % a year earlier.
API endpoints for this dataset
Intercure Ltd vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Intercure Ltd reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Intercure Ltd and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Intercure Ltd | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Intercure Ltd's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs 318.4% for Intercure Ltd. Intercure Ltd's share of combined industry revenue moved from 0.01% to 0.05%, a gain of 0.04 percentage points.
Intercure Ltd's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Intercure Ltd | No | Yes | Yes | No |
| Competitors combined (20) | ||||
| High-Confidence Competitors (4) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 25.00 % (2 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
INCR Stock Performance relative to its Competitors
INCR Stock Performance relative to High-Confidence Competitors
INCR Stock Performance relative to Similar-Size Competitors
INCR Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Lexaria Bioscience Corp | 282.9% | Outperformed |
| 2 | Cronos Group Inc | 282.9% | Outperformed |
| 3 | Aurora Cannabis Inc | 282.9% | Outperformed |
| 4 | Organigram Global Inc | 282.9% | Outperformed |
| 5 | Igc Pharma Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Intercure Ltd's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Intercure Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Intercure Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Intercure Ltd |
- | 270.20 |
 Cronos Group Inc |
1,278.96 | 259.21 |
 Tilray Brands Inc |
353.35 | 962.31 |
 Canopy Growth Corporation |
250.15 | 367.40 |
 Earth Science Tech Inc |
25.52 | 34.65 |
 Zerostack Corp |
25.20 | 40.03 |
| SUBTOTAL | 2,002.38 | 2,565.77 |
Sign in to see all competitors of Intercure Ltd .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Intercure Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Intercure Ltd's Competitors Named by the Company
Competitive relationships identified from Intercure Ltd reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Canopy Growth Corporation | Company report | 85% |
| Bedrocan International B.V. | Company report | 85% |
| Seah Medical Group | Company report | 85% |
| Village Farms Crop | Company report | 85% |
| Aurora Cannabis Inc. | Company report | 85% |
| Cronos Group | Company report | 85% |
| Breath Of Life Pharma, Ltd. | Company report | 85% |
| IM Cannabis Corp. | Company report | 85% |
Company report basis, confidence, active dates and source counts for Intercure Ltd's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Intercure Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Tilray Brands Inc | Beverage Alcohol Business 39.47 % |
| Canopy Growth Corporation | Cannabis Net Revenue 51.21 % |
| Cannapharmarx Inc | Operating Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Intercure Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Intercure Ltd | - | 600,444 | -81,742 |
| Cronos Group Inc | 1,279 | 424,938 | 129,843 |
| Tilray Brands Inc | 353 | 267,681 | -41,672 |
| Canopy Growth Corporation | 250 | 325,706 | -156,339 |
| Earth Science Tech Inc | 26 | - | - |
| Zerostack Corp | 25 | - | - |
| PEERS TOTAL | 2,002 | 311,686 | -72,865 |
Intercure Ltd's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Cronos Group Inc | Other countries 8.98 % |
| Tilray Brands Inc | EMEA 56.59 % |
| Zerostack Corp | DE 92.55 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Intercure Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 491 companies in Intercure Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Intercure Ltd ranks #339 of 491 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 988, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,280,038 | 23.96 % |
| 2 | Johnson and Johnson | 685,131 | 12.82 % |
| 3 | Abbvie Inc | 520,479 | 9.74 % |
| 4 | Merck and Co Inc | 365,659 | 6.84 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 339 | Intercure Ltd | 33 | 0.00 % |
Market cap and industry share for the rest of Intercure Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-10.
Intercure Ltd's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 334 | Telomir Pharmaceuticals Inc | 35 | -51.85 % |
| 335 | Skye Bioscience Inc | 33 | -46.42 % |
| 336 | Lite Strategy Inc | 33 | -55.35 % |
| 337 | Bioharvest Sciences Inc | 33 | -75.46 % |
| 338 | Annovis Bio Inc | 1,234 | 12.3% |
| 339 | Intercure Ltd | 33 | 174.07 % |
| 340 | Adicet Bio Inc | 1,234 | 12.3% |
| 341 | Grace Therapeutics Inc | 1,234 | 12.3% |
| 342 | Nextcure Inc | 1,234 | 12.3% |
| 343 | Elicio Therapeutics Inc | 1,234 | 12.3% |
| 344 | Aardvark Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Intercure Ltd's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-10. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Intercure Ltd's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (446 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 12.28 % | 37.92 % (avg) | -25.6 pp |
| Operating Margin | -10.08 % | industry median | -15.3 pp |
| EBITDA Margin | -16.32 % | -6.30 % (avg) | -10.0 pp |
| Capital Intensity (Capex / Revenue) | 1.31 % | 7.51 % (avg) | -6.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Intercure Ltd's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | -16.65 % | -33.18 % | 318.38 % |
| Operating Margin | -11.69 % | -28.14 % | -10.08 % |
| Return on Invested Capital | -3.17 % | -5.11 % | -3.12 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Intercure Ltd's Strategic Group Map
Intercure Ltd is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Intercure Ltd's trailing-12-month revenue growth of 318.4% and operating margin of -10.1% compares with an average of 312.4% growth and -11.7% margin across its 8 closest peers by combined growth, margin and ROIC -- Intercure Ltd sits above that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Intercure Ltd's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Intercure Ltd falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.3% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Intercure Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 988 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.31 % vs industry average 7.51 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Intercure Ltd's dedicated Suppliers and Customers pages, not here.
Intercure Ltd's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Intercure Ltd falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Intercure Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Operating margin 15.3 points below the industry median.
- Return on equity 29.4 points below the industry aggregate.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of competitors (47.40 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-17.6% annualized).
Methodology: see Methodology: SWOT Analysis.
Intercure Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Intercure Ltd | 0.22 | 1.50 | 0.15 |
| Cronos Group Inc | 15.24 | 19.71 | - |
| Tilray Brands Inc | 0.69 | 2.27 | 0.22 |
| Canopy Growth Corporation | 2.01 | 3.43 | 0.42 |
| Earth Science Tech Inc | 0.36 | 1.35 | 0.01 |
| Zerostack Corp | 0.67 | 1.33 | 0.38 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Intercure Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Intercure Ltd | Q4 2025 | +318.4 % | - |
| Cronos Group Inc | Q2 2026 | +269.5 % | - |
| Tilray Brands Inc | Q3 2026 | +22.8 % | - |
| Canopy Growth Corporation | Q2 2026 | +12.9 % | - |
| Earth Science Tech Inc | Q2 2026 | +11.6 % | +51.2 % |
| Zerostack Corp | Q2 2026 | +40.7 % | - |
| PEERS TOTAL | +67.8 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Intercure Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Intercure Ltd | Q4 2025 | +317.6 % | +199.9 % |
| Cronos Group Inc | Q2 2026 | +66.5 % | -80.8 % |
| Tilray Brands Inc | Q3 2026 | +18.2 % | - |
| Canopy Growth Corporation | Q2 2026 | +8.9 % | -50.5 % |
| Earth Science Tech Inc | Q2 2026 | +37.5 % | -89.9 % |
| Zerostack Corp | Q2 2026 | +32.5 % | - |
Intercure Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Intercure Ltd | - | - | - |
| Cronos Group Inc | 6.70% | 6.90% | 7.25% |
| Tilray Brands Inc | - | - | - |
| Canopy Growth Corporation | - | - | - |
| Earth Science Tech Inc | 44.02% | 64.38% | 66.17% |
| Zerostack Corp | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Intercure Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Intercure Ltd | - | - |
| Cronos Group Inc | 17.95 | 4.93 |
| Tilray Brands Inc | - | 0.37 |
| Canopy Growth Corporation | - | 0.68 |
| Earth Science Tech Inc | 17.60 | 0.74 |
| Zerostack Corp | - | 0.63 |
| PEERS AVERAGE | - | 0.78 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.